Simon Property Raises 2026 FFO Forecast on Strong Tenant Sales
Earnings James Calloway

Simon Property Raises 2026 FFO Forecast on Strong Tenant Sales

Simon Property Group (SPG) raised its 2026 FFO guidance after a strong Q2, with tenant sales up 13.9% and base rent up 6.3%. Occupancy held at 96%.

Target Hits 52-Week High as Back-to-School Strategy Gains Traction
Analysis Daniel Marsh

Target Hits 52-Week High as Back-to-School Strategy Gains Traction

Target (TGT) closed at a 52-week high of $152.02, up 1.55%, as investors bet on a strong back-to-school season. The stock now trades 12% above analysts' average target, raising stakes for upcoming earnings.

TGT AMZN WMT COST
Yen's Slide Persists Despite Record Speculative Short Squeeze
Forex Rebecca Torres

Yen's Slide Persists Despite Record Speculative Short Squeeze

The yen weakened to 159.14 despite a sharp reduction in speculative shorts, as BOJ's hawkish tone failed to offset dollar strength and inflation concerns.

Bristol Myers Unveils $2.3B Houston Facility for Flexible Drug Production
Analysis Daniel Marsh

Bristol Myers Unveils $2.3B Houston Facility for Flexible Drug Production

Bristol Myers Squibb (BMY) will build a $2.3 billion drug-manufacturing campus in Houston, supporting small molecules, biologics, and antibody-drug conjugates, with nearly 500 skilled jobs.

BMY LLY JNJ RHHBY AZN
Jones Act Waiver Extended 90 Days with Stricter Per-Voyage Scrutiny
Regulation James Calloway

Jones Act Waiver Extended 90 Days with Stricter Per-Voyage Scrutiny

President Trump extends Jones Act waiver for 90 days, but new approvals require case-by-case review. Oil jumps 5% as Hormuz uncertainty persists.

USO XLE
Gold Hits Nine-Week High as Chinese Buying Spurs Bullish Outlook
Commodities Rebecca Torres

Gold Hits Nine-Week High as Chinese Buying Spurs Bullish Outlook

Gold climbed to its highest in nine weeks, buoyed by Chinese central bank purchases and technical momentum, with analysts eyeing $4,500 as inflation data looms.

GLD SLV HSBC UBS JPM SNEX
Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran
Markets Daniel Marsh

Silence Therapeutics Soars on Quarterly Dosing Data for Divesiran

Silence Therapeutics (SLN) surged 25%+ as Phase 2 data validated 12-week dosing for divesiran in polycythemia vera, with 88% response rate versus 19% placebo.

PTGX
Sandisk Shares Climb as Analysts Reassess Post-Earnings Drop
Earnings James Calloway

Sandisk Shares Climb as Analysts Reassess Post-Earnings Drop

Sandisk shares rose 1.9% on Monday as analysts reframed last week's earnings selloff, with Argus upgrading to Buy and a $1,600 target.

SNDK WDC MU STX
CEVA Stock Plunges 16% as Royalty Growth Trails AI Licensing Boom
Earnings James Calloway

CEVA Stock Plunges 16% as Royalty Growth Trails AI Licensing Boom

CEVA shares tumbled 16% after Q2 results showed a licensing surge but royalty growth of only 1%, as AI design wins have yet to generate production revenue.

CEVA
Tesla Stock Stalls Despite Retail Buying Surge as Valuation Hits 300x Earnings
Markets Daniel Marsh

Tesla Stock Stalls Despite Retail Buying Surge as Valuation Hits 300x Earnings

Tesla shares remained nearly unchanged despite a tripling of retail purchases to $372 million, as valuation concerns persist with the stock trading at over 300 times earnings.

TSLA
S&P 500 Options Sentiment Hits 4-Year Bullish Peak as Rally Loses Steam
Markets Daniel Marsh

S&P 500 Options Sentiment Hits 4-Year Bullish Peak as Rally Loses Steam

S&P 500 call-to-put ratio hits 0.9, a four-year high, even as index slips. JPMorgan raises target to 8,000, but limited upside remains.

JPM RY C IBKR
Meta Stock Slips as Muse Hype Meets $145B Spending Reality
Technology Sarah Chen

Meta Stock Slips as Muse Hype Meets $145B Spending Reality

Meta shares faded after the Muse Glimmer launch, with investors questioning whether AI offerings justify the company's massive $145B capital spending plan.

META